PIRAMAL PHARMA
Stock Radar: 100% rally in a year! This pharma company takes support above 50-EMA; time to buy the dip?
Piramal Pharma's stock, after reaching record highs, experienced profit-taking but is showing signs of a bullish comeback. Experts suggest buying the stock, citing its rebound from the 50-day EMA and strong trading volume, with a potential target of Rs 280-286 in the coming weeks.
HCL Technologies, Paytm, and BSE among stocks that mutual funds bought and sold in October
Indian mutual funds purchased Rs 872 billion worth of stocks in September, focusing on large-cap stocks like Reliance Industries and HDFC Bank. Mid-cap additions included 360 One Wam and Tata Chemicals, while small-cap additions favored Sansera Eng and Sundaram Clayton. Mutual funds actively adjusted their portfolios throughout October, indicating a dynamic market approach.
Trump & Tariffs: Pharma sector might escape the inevitable tariff troubles. 6 pharma stocks, 5 with an upside potential of up to 38%
Exactly eight years ago, in 2016, when a reality TV star became US president, the global markets went into sharp decline on the day of surprise victory. In 2024, the reaction is the opposite ¨C markets are rejoicing at his return. While there is nothing wrong in having a party, better be cognizant of some of the things the next US president brings to the table. One would be tariff wars. While China will be the main focus, there are areas where India will be in the picture. But there is one sector that is unlikely to face any trouble: Pharmaceuticals. There are reasons why it might escape the headwinds, in some cases the change in regime might act as another tailwind.
Share market update: Most active stocks in today's market in terms of volume
The NSE Nifty index closed 270.75 points up at 24484.05
- Go To Page 1
Ahead of Market: 10 things that will decide stock action on Monday
Indian benchmark equity indices gained during a special one-hour "muhurat" trading session on Friday, marking the Diwali festival, driven by auto stocks boosted by positive monthly sales data.
Buy IT stocks on dips; not big on pharma but like specific stocks: Chakri Lokapriya
Chakri Lokapriya highlights a selective approach toward pharma, favoring Cipla and Piramal for potential gains due to specific catalysts like FDA approvals. He recommends buying IT stocks like HCL Tech and Mphasis amid market dips, driven by robust cloud computing growth predictions. Trent and Titan continue to show strong urban consumption trends.
Stock Radar: 170% rally in a year! Multibagger pharma stock breaks out from 6-week consolidation; time to buy?
Piramal Pharma has broken out from a 6-week consolidation on weekly charts, now trading above key moving averages and is positioned to rise toward Rs 280 in the next 3-4 weeks. This progression follows a strong uptrend and a breakout from the previous resistance levels.
Piramal Pharma deploying USD 85 mn capex this fiscal: Nandini Piramal
Piramal Pharma is investing USD 85 million this fiscal for initiatives like capacity expansion and maintenance. They have already used USD 30 million in the first half. Part of the funds will be for domestic use and some for the US. The company aims to reach USD 2 billion in revenue by FY30.
Corrections are opportunities, only if you buy right: 5 mid-cap stocks owned by certain business houses with upside potential of up to 49%
Nine out of 10 stocks have declined in the past three weeks. Little wonder that doubt, confusion, and fear are the overwhelming feelings on the street. This is the exact opposite of what was happening just a couple of months back. In that extremely bullish period, even cats and dogs were flying with half-billion-dollar market caps. That optimism did not last, and neither will the current pessimism. Equilibrium will return to the market. So what should you do in this phase of pessimism (which might last a while longer)? The simple answer: Look for stocks with the comfort of ¡°management with ability¡±. This is very different from ¡°management¡¯s ability¡±.
Dharmesh Shah on 2 sectors to bet on in a volatile market
Nifty has strong support at 23,800, with resistance around 24,600 to 24,700. Going short now is not advisable¡ªany positive news could trigger a pullback to 24,500 or 24,600
Sandip Sabharwal on defence and railway plays which are still worth a bet
?So, just hold on because the tailwinds for the sector seem to be there in the near term. Hold on to what we have unless and until we get better prices.
Hot stocks: Brokerage view on IndusInd Bank, Dixon Technologies, Colgate, ITC and Piramal Pharma
Brokerage firm Jefferies has retained its buy recommendation for IndusInd Bank and Piramal Pharma, while JP Morgan holds a neutral stance on Colgate. Additionally, Investec and Goldman Sachs have also issued buy ratings for Dixon Technologies and ITC.
Piramal Pharma shares soar 15% after reporting 4-fold jump in Q2 profit
Piramal Pharma Share Price: The company's revenue from operations increased to Rs 2,242 crore in the second quarter, up 17% year-on-year from Rs 1,911 crore in the same period last year, mainly due to strong growth in its CDMO business.
Piramal Pharma Q2 Results: Net profit jumps over 4-fold to Rs 23 cr; revenue at Rs 2,242 cr
Piramal Pharma reported a significant increase in consolidated net profit for Q2, growing from Rs 5 crore last year to Rs 23 crore. Revenue also rose to Rs 2,242 crore. Key drivers include strong growth in the CDMO and CHG businesses, with expansion plans in Lexington, Dahej, and Digwal to meet rising demand.
Stocks in news: ITC, Adani Wilmar, HUL, United Spirits, Adani Power
Adani Power will consider raising funds worth Rs 5,000 crore by way of public issue and/or private placement of non-convertible debentures (NCDs) in one or more tranches.
Piramal Pharma Q2 Results: Co posts net profit of Rs 23 crore
The contract research and manufacturing services (CDMO) revenues rose 24% YoY to Rs 1324 crore led by order inflow momentum, especially for on-patent commercial manufacturing.
Stock Radar: 120% rally in 1 year! Flag pattern seen in this multibagger pharma stock; time to buy?
Piramal Pharma Ltd has doubled investors' wealth over the past year. After breaking out from a Rounding Bottom and forming a Flag pattern, experts suggest it could reach above Rs 300 in the next 6-7 months. The stock recently hit a high of Rs 244 and is now seen consolidating around Rs 200.
Piramal Pharma stock in focus on $80 million expansion plan for Kentucky injectables facility
Piramal Pharma Solutions, is investing $80 million to expand its Lexington facility, doubling capacity by Q1 2027 to meet growing injectables demand, supporting its ADC manufacturing program.
Stocks in news: TCS, Tata Power, IRCTC, Mankind Pharma, Bank of Maharashtra, SpiceJet
Mankind Pharma announced that it would raise up to Rs 10,000 crore through issuance of non-convertible debentures (NCD) and commercial papers.
Stocks in news: Biocon, SJVN, Adani Green, Union Bank, Nuvama Wealth
Stocks in news: Markets saw a nearly 1% rise on the monthly expiry day, driven by favorable cues. Key stocks in focus include Biocon, SJVN, Adani Green, Union Bank, and Nuvama Wealth due to various developments such as agreements, joint ventures, property sales, and potential equity sales.
Load More
